Non-HBV Assets

RNA interference, or RNAi, is considered one of the most important discoveries in the field of biomedical science in the last decade. In fact, in 2006 the scientists who discovered the mechanisms for RNAi were awarded the Nobel Prize in Medicine.


LNP and RNAi technology has the potential to generate a broad new class of therapeutics that take advantage of the body’s own natural processes to silence disease-causing genes — or more specifically to eliminate gene-products, from the cell. Arbutus’ proprietary LNP Delivery Platform (LNP) makes possible the successful delivery and enablement of RNAi drugs. Our LNP represents the most widely adopted delivery technology in RNAi, enabling eight clinical trials and administered to hundreds of patients to date. Because LNP can enable a wide variety of nucleic acid payloads, including messenger RNA (mRNA), we continue to see new product development and partnering opportunities based on our industry-leading delivery expertise.